KRAS mutant lung adenocarcinoma cancer shows a poor prognosis compared with other solid tumors and molecular subtypes of lung cancer due in part to the progress of resistance to currently systemic or targeted therapy [5]. This evidence concerns the gene KRAS and lung cancer.